Brought to you by 
Aventis to co-develop, -promote Regeneron's VEGF Trap
Sep 2003
Executive Summary
Aventis agreed to pay Regeneron up to €460mm ($510mm) for worldwide exclusive joint development and marketing rights (excluding Japan) to Regeneron's lead anti-angiogenesis compound VEGF Trap (vascular endothelial growth factor), which is in Phase I clinical trials for solid-tumors and non-Hodgkin's lymphoma.
Deal Industry
-
Biotechnology
- Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Includes Equity
- R+D and Marketing-Licensing
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aventis to co-develop, -promote Regeneron's VEGF Trap
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice